Literature DB >> 30942483

Bone development and remodeling in metabolic disorders.

Jenny Serra-Vinardell1,2, Neus Roca-Ayats1, Laura De-Ugarte3,4, Lluïsa Vilageliu1, Susanna Balcells1, Daniel Grinberg1.   

Abstract

There are many metabolic disorders that present with bone phenotypes. In some cases, the pathological bone symptoms are the main features of the disease whereas in others they are a secondary characteristic. In general, the generation of the bone problems in these disorders is not well understood and the therapeutic options for them are scarce. Bone development occurs in the early stages of embryonic development where the bone formation, or osteogenesis, takes place. This osteogenesis can be produced through the direct transformation of the pre-existing mesenchymal cells into bone tissue (intramembranous ossification) or by the replacement of the cartilage by bone (endochondral ossification). In contrast, bone remodeling takes place during the bone's growth, after the bone development, and continues throughout the whole life. The remodeling involves the removal of mineralized bone by osteoclasts followed by the formation of bone matrix by the osteoblasts, which subsequently becomes mineralized. In some metabolic diseases, bone pathological features are associated with bone development problems but in others they are associated with bone remodeling. Here, we describe three examples of impaired bone development or remodeling in metabolic diseases, including work by others and the results from our research. In particular, we will focus on hereditary multiple exostosis (or osteochondromatosis), Gaucher disease, and the susceptibility to atypical femoral fracture in patients treated with bisphosphonates for several years.
© 2019 SSIEM.

Entities:  

Keywords:  CYP1A1; EXT2; GGPPS; Gaucher disease; atypical femoral fracture; bone development; bone remodeling; multiple hereditary exostosis

Mesh:

Substances:

Year:  2019        PMID: 30942483     DOI: 10.1002/jimd.12097

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  5 in total

1.  Desktop-Stereolithography 3D Printing of a Polyporous Extracellular Matrix Bioink for Bone Defect Regeneration.

Authors:  Yunxiang Luo; Hao Pan; Jiuzhou Jiang; Chenchen Zhao; Jianfeng Zhang; Pengfei Chen; Xianfeng Lin; Shunwu Fan
Journal:  Front Bioeng Biotechnol       Date:  2020-11-06

2.  Bisphosphonates Reduce Smoking-Induced Osteoporotic-Like Alterations by Regulating RANKL/OPG in an Osteoblast and Osteoclast Co-Culture Model.

Authors:  Sheng Zhu; Victor Häussling; Romina H Aspera-Werz; Tao Chen; Bianca Braun; Weidong Weng; Tina Histing; Andreas K Nussler
Journal:  Int J Mol Sci       Date:  2020-12-23       Impact factor: 5.923

Review 3.  The Role of Sphingolipid Metabolism in Bone Remodeling.

Authors:  Tang Qi; Liao Li; Tian Weidong
Journal:  Front Cell Dev Biol       Date:  2021-11-29

4.  Changes in skeletal dysplasia nosology.

Authors:  Maria Claudia Jurcă; Sânziana Iulia Jurcă; Filip Mirodot; Bogdan Bercea; Emilia Maria Severin; Marius Bembea; Alexandru Daniel Jurcă
Journal:  Rom J Morphol Embryol       Date:  2021 Jul-Sep       Impact factor: 0.833

5.  Coumarin Ameliorates Impaired Bone Turnover by Inhibiting the Formation of Advanced Glycation End Products in Diabetic Osteoblasts and Osteoclasts.

Authors:  Eun-Jung Lee; Min-Kyung Kang; Yun-Ho Kim; Dong Yeon Kim; Hyeongjoo Oh; Soo-Il Kim; Su Yeon Oh; Woojin Na; Young-Hee Kang
Journal:  Biomolecules       Date:  2020-07-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.